Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

ContextVision – Mandatory notification of trade – primary insider

STOCKHOLM – October 22, 2021 – Fredrik Palm, CEO of ContextVision, has on October 22[nd], 2021 purchased 2,500 shares in ContextVision AB at an average price of NOK 22.47 per share. After the transaction, Mr Palm holds a total of 30,700 shares in ContextVision AB. With reference to Section 4-2 of the Norwegian Securities Trading Act ("STA"), kindly note the following primary insider share transaction: Name of listed entity: ContextVision ABISIN number: SE0014731154Stock ticker: CONTXName of primary insider: Fredrik PalmRelation to listed entity: CEOTrade: 2,500 sharesDate:

Dignitana publishes October newsletter

Dignitana AB today publishes the October newsletter highlighting prominent media coverage for DigniCap and activities for Breast Cancer Awareness Month. To read the newsletter click here   or visit Dignitana.com .The Dignitana InBrief newsletter is published monthly and posted at www.dignitana.com as part of Dignitana's commitment to provide ongoing communication to the market. To receive future Dignitana news directly to your email,

New shares of Bioretec Ltd subscribed with option rights have been registered with the trade register

Bioretec Ltd                         Company announcement    22 October 2021 at 12.30 p.m.An aggregate number of 125,487 new shares of Bioretec Ltd have been subscribed for with option rights under option program 2021-1. The new shares have today on 22 October 2021 been registered with the trade register maintained by the Finnish Patent and Registration Office. The total subscription price of EUR 125.63 will be recorded in Bioretec's reserve of invested unrestricted equity, and the company's share capital remains unchanged. Following the registration of the new shares, the total number

Cell Impact reports third quarter results: Continued strong growth

Cell Impact AB (Nasdaq First North GM: CI B) reports the following financial summary for the third quarter.· Total revenues for the first quarter amounted to SEK 27.5 million, which is growth of 224 percent for the quarter. · Operating result was SEK -14.4 million (-5.7). · The Group's result after financial items was SEK -14.7 million (-6.1). · Earnings per share attributable to the shareholders of the Parent Company totaled SEK -0.25 (-0.12). · Equity was SEK 149.3 million (52.3) or SEK 2.54 per share (1.01) on the balance sheet date. · Debt/equity ratio was 73% (59%) on

Nordax Bank receives affirmed investment grade rating from Nordic Credit Rating (BBB, stable outlook)

Nordax Bank AB (publ) (“Nordax”) has, taking into consideration the acquisition of Bank Norwegian, received an affirmed investment grade rating from the rating institute Nordic Credit Rating with the rating BBB, stable outlook. To have a diversified funding structure is a cornerstone in Nordax’s funding strategy and reduces Nordax’s liquidity risk and enables it to create a larger, more optimal financing mix over time. Being an active issuer in the capital market is part of the strategy. The credit rating from Nordic Credit Rating further strengthens Nordax’s possibilities of getting

The Riksbank’s Business Survey: “As soon as you find one component, you realise you’re missing another”

Economic activity has continued to strengthen for major Swedish companies since the spring due to strong domestic and global demand. At the same time, there are major disruptions in output and deliveries, which are increasing costs and the need to raise sales prices.“The entire transport market is a bit shaky” For parts of the business sector, the supply problems have worsened since the Riksbank’s last survey this May. Parts of the manufacturing sector have periodically been forced to limit output due to logistics problems in combination with shortages of key components such as

New distributor in the US for LightAir

LightAir has signed a distribution agreement for the US market with market-leading Almo Corporation. The collaboration begins immediately with a first order for Swedish-developed air purifiers, valued at approximately SEK 2 million.Over the past six months, LightAir has established new partnerships with a handful of new distributors in a number of regions. The latest addition is Almo Corporation, which is the largest independent distributor of consumer products, as well as furniture and household appliances, in the United States. They work with over 2,000 independent dealers through eight

Smart mothers, the champions of learning

Learning must go on, even during a pandemic. When Indian schools were closed, Getinge’s partner Pratham mobilized mothers through phone-based outreach and resources, to enable them to become champions of learning. During the pandemic, large parts of India were in strict lockdowns and many schools in the Assam region were closed. For Getinge’s partner Pratham, an innovative learning organization working to improve the quality of education in India, there was no doubt: learning must go on. “A supportive learning environment at home can be a big contributor to the overall

Inwido AB’s Nomination Committee for the 2022 Annual General Meeting

Based on the ownership structure as of August 31, 2021 the largest shareholders in Inwido AB (publ) in terms of voting rights were consulted and expressed their desire to participate in the nomination process. The Nomination Committee has been appointed by Swedbank Robur Fund, the fourth AP Fund and the Lannebo Fund. Each has appointed a representative, as detailed below, who, together with Per Bertland, the chairman of the board, constitute Inwido´s Nomination Committee.Members of the Nomination Committee: Bo Lundgren, Swedbank Robur Fund (Chairman of the Nomination Committee) Thomas

Stockmann’s Interim report for January–September 2021 will be published as an Interim Management Statement

STOCKMANN plc, Other information disclosed according to the rules of the Exchange 22.10.2021 at 11.00 EETStockmann plc will publish its Interim report for January–September 2021 as a shorter Interim Management Statement. The publishing date and time will remain the same, 29 October 2021 at 8:00.The press and analyst briefing will be held on 29 October 2021 at 10:00 as a live webcast, that can be followed by this link  or on the address stockmanngroup.com.  The recording and presentation material

Invitation to Pexip Capital Markets Day

(Oslo, Norway, October 22, 2021) Pexip Holding ASA (“Pexip”, Oslo Børs Ticker: PEXIP) invites investors, analysts, media and other stakeholders to a Capital Markets Day (CMD) on Thursday December 9 2021, from 09:00 to 11:30 CET. The event will take place at Oslo Konserthus (Lille Sal), Munkedamsveien 14, Oslo, Norway, and a live webcast of the event will also be streamed via https://investor.pexip.comEvent details for the Pexip Capital Markets Day 2021 Date: December 9, 2021 Time: 09:00 - 11:30 CET For registration to the event, please follow this link and select either in-person

BioStock: Targinta’s CEO on TARG10 and the spin-off

Targinta has selected its first drug candidate TARG10, which shows an inhibitory effect on tumour growth and reduced metastasis in triple-negative breast cancer. In addition, the company is in an intensive phase where it is preparing for a spin-off from the parent company Xintela. BioStock contacted Targinta’s CEO Per Norlén to learn more about TARG10 and the spin-off.Read the interview with Targinta's CEO Per Norlén at biostock.se: https://www.biostock.se/en/2021/10/targintas-ceo-on-targ10-and-the-spin-off/ This is a press release from BioStock - Connecting Innovation & Capital.

Nepa AB appoints Nomination Committee

STOCKHOLM, Sweden - Nepa, a leading consumer research and analytics company, providing insight solutions to strengthen brands and drive sales by increased marketing effectiveness, has had a Nomination Committee appointed for the company. Nepa AB’s four largest shareholders on September 30, 2021, have in consultation with the Chairman of the Board, Katarina Bonde, appointed the following representatives to serve on the Nomination Committee: - Ulrich Boyer, private investor - Marcus Wahlberg, representing Elementa - Ulrik Grönvall, representing Swedbank Robur - Niclas Öhman,

Irisity wins €0.5m SaaS contract to protect sites across the Netherlands.

Irisity AB (publ): In partnership with Spyke Security Irisity delivers video analytics technology to customers in the Netherlands, with an estimated order value of EUR 0.5 million. Due to the confidential nature of this relationship, and the security applications involved, we are unable to disclose any further details regarding end customers identity or the specifics of the projects. For further information: Andreas Höye, Irisity IR Phone: +46 769 01 34 51 E-mail: andreas.hoye@irisity.com

Publishing of Apetit Plc’s Business Review for January-September 2021

Apetit Plc, Press release, on 22 October 2021 at 10:00 a.m.Apetit Plc will publish its Business Review for January-September 2021 on Friday 29 October 2021 at 8.30 a.m. A separate press conference in relation to the Business Review will not be arranged.Apetit PlcFor further information, please contact:Sanna Väisänen, Director, Corporate Communications and Sustainability, tel. +358 10 402 4041Apetit is a food industry company firmly rooted in Finnish primary production. Our operations are based on a unique and sustainable value chain: we create well-being with vegetables by offering

Restructuring programme of Componenta Castings Ltd has ended

Componenta Corporation Stock Exchange Release, 22 October 2021 at 10:00 EEST The restructuring programme of Componenta Castings Ltd has ended upon the approval of the payment of restructuring debt carried out by the company on 15 October 2021 by the supervisor and the provision of the supervisor’s final account of the restructuring programme to creditors today on 22 October 2021. The Board of Directors of Componenta Corporation has on 13 October 2021 decided to end Componenta Castings Ltd’s (“Componenta Castings”) restructuring programme prematurely. Componenta Castings had previously

Introducing Virtual Lapland: a new way to experience the northern Finnish nature

Explore and enjoy a 3D Arctic environment by Only in LaplandVirtual Lapland is a breathtaking, free VR experience by Only in Lapland, enabling people around the world to immerse themselves in the seasons and sensations of the north. The fully computer-generated environment is a virtual representation of the last wilderness in Europe and offers interactive elements, information, and stories about Lapland, including an animated tale about the Northern Lights. Finnish Lapland's official travel channel, Only in Lapland teamed up with Zoan, the studio behind other popular virtual destinations,

Elicera Therapeutics appoints professor Gunilla Enblad, Key Opinion Leader within the fields of CAR T-cells and B-cell lymphoma, as scientific advisor

Gothenburg, October 22, 2021 - Elicera Therapeutics AB (publ), a clinical stage cell and gene therapy company that develops immunooncological treatments focusing on CAR T-cells and oncolytic viruses, announced today that it has appointed professor Gunilla Enblad, Key Opinion Leader within the fields of CAR T-cells and B-cell lymphoma, as scientific advisor to the company.Dr. Gunilla Enblad is a Senior Consultant in Oncology since 2000 and was Head of Department at the Oncology Clinic at Uppsala University Hospital between 2004 and 2012. Enblad is Professor in Oncology at Uppsala University

DanCann Pharma A/S: Tetra Bio-Pharma Receives Positive Opinion for Orphan Drug Designation for QIXLEEF™ from the European Medicines Agency

COPENHAGEN, Denmark, 22 October 2022, DanCann Pharma A/S ("DanCann Pharma"), a Danish company powered by cannabinoids, hereby on behalf of Tetra Bio-Pharma Inc. (“Tetra” or the “Company”), announce that Tetra Bio-Pharma - a leader in cannabinoid-derived drug discovery and development – yesterday announced that the European Medicines Agency (EMA) Committee for Orphan Medicinal Products (COMP) issued a positive opinion on the Company's application for Orphan Drug Designation (ODD) for its investigational medicine QIXLEEF™ as a potential treatment for Complex Regional Pain Syndrome (CRPS), a

BioStock: Ultimovacs receives dual FDA Fast Track for UV1

Ultimovacs’ mission to develop a cancer vaccine just received a significant boost. The FDA has granted dual Fast Track designation for the company’s candidate UV1 as an add-on therapy to checkpoint inhibitors in advanced malignant melanoma patients. The designation potentially provides expedited review of UV1 for approval.Read the article at biostock.se : https://www.biostock.se/en/2021/10/ultimovacs-receives-dual-fda-fast-track-for-uv1/ This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se

Yoav Ben-Eli has been nominated as CEO of Crown Energy

On September 15, 2021 Crown Energy AB(publ) (“Crown Energy”) has announced that Yoav Ben-Eli was appointed as CEO of Crown Energy, subject to an exemption from the residency requirement for the CEO, as stipulated in Chapter 8, Section 30 in the Swedish Companies Act (2005:551), at the Swedish Companies Registration Office (Sw.Bolagsverket). The exemption from the residency requirement has been confirmed by SCRO and Yoav Ben-Eli will now assume position as the CEO, and that Andreas Forssell is resume as the company’s deputy CEO

I-Tech AB (publ) Interim report Q3 2021

I-Tech AB (publ) (ticker: ITECH) publish the interim report for the third quarter 2021 Click here on the 22 October 2021 at 11:00 to follow the webcast Summary of the period ” Positive result with a strong contribution from a growing customer base ” · Net turnover for the period amounted to 13 811 (11 956) kSEK, corresponding to an increase in turnover of 16% (-2%). Operating profit/loss amounted to 837 (-723) kSEK. July to September 2021 · No important events occurred during the period. Important events after the period

INVITATION: INVISIO invites you to a conference call October 29 at 10:00 CEST

INVISIO is pleased to invite press, investors and analysts to a conference call on October 29 at 10.00 CEST where CEO Lars Højgård Hansen will present the Interim Report January – September 2021.The conference call, which will be held in English, will begin with a presentation of the report followed by a Q&A session. The Interim Report January – September 2021 will be published on October 28, 2021, at 14:00 CEST.Phone number for the conference:To participate in the conference call, use the dial-in numbers below. Please dial in 5-10 minutes prior to the scheduled start time in order to

There are no items matching the current filter
There are no more items matching the current filter
Back to top